Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukaemia with a Consideration of Socio-economic Characteristics: A Retrospective Study from a Single Centre

Abstract Introduction To compare the efficacy and safety of generic and branded imatinib in adults with newly diagnosed chronic myeloid leukaemia in the chronic phase (CML-CP), we retrospectively reviewed data from patients CML-CP receiving generic or branded imatinib. Patients and Methods A propensity score matching (PSM) study was performed. Cox regression model was used to identify factors associated with responses and outcomes. Results 442 adults receiving generic imatinib (n=236) or Glivec® (n=206) were included. There were more patients with rural household registration (P Conclusions Socio-demographics might influence the tyrosine kinase inhibitor that patients chose. Generic and branded imatinib as first-line therapy had comparable efficacy and safety in CML-CP patients.